Medical Marijuana Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome
Medical Marijuana, Inc. (OTC:MJNA) major investment company AXIM® Biotechnologies announced the enrolment of 40 patients and started its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.
As quoted in the press release:
Selected from a pool of over 400 patients, 40 trial patients aged 18-65 will be subject to a randomized, double-blind, cross-over trial of 8 weeks. Patients will receive a maximum 6 chewing gums per day, either containing 50 mg of cannabidiol per chewing gum in case of the CanChew chewing gum, or a placebo chewing gum.
Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017.